300406.SHE Beijing Strong Biotechnologies Inc
- Market cap
- CNY 7.36B
- P/E
- 28.5x
- P/B
- 2.03x
- ROE
- 12.3%
- Dividend yield
- 7.30%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300406.SHE undervalued?
Graham number300406.SHE trades 60.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Strong Biotechnologies Inc fundamental analysis
No fundamental analysis for Beijing Strong Biotechnologies Inc yet.
Beijing Strong Biotechnologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Strong Biotechnologies Inc
Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. It provides biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen, as well as antithrombi…
Full company profileBeijing Strong Biotechnologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Strong Biotechnologies Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 667M | 694M | 774M | 841M | 848M | 1.60B | 1.51B | 1.74B | 1.66B | 1.36B | 1.37B |
| Gross Profit | 457M | 499M | 530M | 577M | 520M | 1.15B | 1.13B | 1.30B | 1.30B | 1.08B | 1.11B |
| Operating Income | 311M | 324M | 347M | 378M | 153M | 536M | 455M | 594M | 624M | 475M | 570M |
| EBITDA | 310M | 331M | 343M | 382M | 196M | 591M | 554M | 658M | 701M | 357M | 563M |
| Net Income | 272M | 273M | 301M | 332M | 112M | 406M | 389M | 524M | 533M | 190M | 444M |
| EPS | 0.54 | 0.55 | 0.57 | 0.66 | 0.21 | 0.69 | 0.66 | 0.88 | 0.90 | 0.32 | 0.76 |
| Balance Sheet | |||||||||||
| Total Assets | 1.47B | 1.78B | 1.86B | 2.15B | 3.96B | 4.32B | 4.61B | 5.18B | 5.57B | 5.05B | 4.93B |
| Total Liabilities | 83.1M | 249M | 163M | 183M | 540M | 1.41B | 1.34B | 1.45B | 1.44B | 1.27B | 1.33B |
| Shareholders' Equity | 1.39B | 1.53B | 1.70B | 1.97B | 3.20B | 2.87B | 3.27B | 3.72B | 4.14B | 3.79B | 3.61B |
| Cash & Short-term Investments | 792M | 683M | 480M | 226M | 582M | 383M | 341M | 724M | 1.04B | 540M | 588M |
| Total Debt | 20.7M | 61.7M | 64.0M | 89.8M | 300M | 1.12B | 1.10B | 1.13B | 1.13B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 243M | 208M | 256M | 189M | 123M | 341M | 396M | 590M | 614M | 565M | - |
| Capital Expenditure | 76.6M | 25.2M | 73.1M | 61.4M | 17.2M | 65.2M | 96.5M | 148M | 67.6M | 39.2M | 16.8M |
| Free Cash Flow | 167M | 183M | 183M | 127M | 106M | 276M | 300M | 437M | 546M | 526M | 552M |
| Ratios | |||||||||||
| ROE | 19.6% | 17.9% | 17.7% | 16.8% | 3.5% | 14.1% | 11.9% | 14.1% | 12.9% | 5.0% | 12.3% |
| ROA | 18.5% | 15.4% | 16.1% | 15.4% | 2.8% | 9.4% | 8.4% | 10.1% | 9.6% | 3.8% | 9.0% |
| Net Profit Margin | 40.7% | 39.3% | 38.8% | 39.4% | 13.2% | 25.4% | 25.8% | 30.1% | 32.1% | 14.0% | 32.3% |
| Debt to Equity | 0.01x | 0.04x | 0.04x | 0.05x | 0.09x | 0.39x | 0.34x | 0.30x | 0.27x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Strong Biotechnologies Inc dividends
- Dividend yield
- 7.30%
- Forward dividend
- 1.05 CNY
- Payout ratio
- 282.9%
- Ex-dividend date
- Sep 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 537M | 0.92 | 282.9% |
| 2024 | CNY 124M | 0.21 | 23.3% |
| 2023 | CNY 58.6M | 0.10 | 11.2% |
| 2022 | CNY 58.8M | 0.10 | 15.1% |
| 2021 | CNY 58.4M | 0.10 | 14.4% |
| 2020 | CNY 74.5M | 0.14 | 66.4% |
| 2019 | CNY 74.5M | 0.15 | 22.5% |
| 2018 | CNY 75.3M | 0.14 | 25.0% |
| 2017 | CNY 150M | 0.30 | 55.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on May 3, 2016.
Who owns Beijing Strong Biotechnologies Inc
- Insiders 64.43%
- Institutions 2.38%
- Public & others 33.18%
- Shares outstanding 586M
- Free float 218M
Beijing Strong Biotechnologies Inc company profile
- Company name
- Beijing Strong Biotechnologies Inc
- Ticker
- 300406.SHE
- ISIN
- CNE100001Y26
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 998
- Fiscal year end
- December
- Address
- Kuang Yi Building, Beijing, China, 100191
- Phone
- 86 10 8224 7199
- Website
- bsbe.com.cn
About Beijing Strong Biotechnologies Inc
Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. It provides biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen, as well as antithrombin III, von Willebrand factor antigen, protein S activity, protein C, lupus anticoagulant, fibrin degradation products, and d-dimer. The company also offers blood grouping card comprising ABO blood type anti stereotype detection card, DiaClon ABD-confirmation, and DiaClon ABO/D+ reverse grouping for patients; and automatic coagulation analyzer, automatic biochemistry analyzer, fully automatic chemiluminescence immunoassay analyzer, and automated blood groupings analyzer. It sells its products under the Kingsley and Meichuang brand names. Beijing Strong Biotechnologies,Inc. was founded in 2001 and is based in Beijing, China.
Beijing Strong Biotechnologies Inc management
5- Mr. Wei LiuCFO & Accounting Supervisor · born 1969
- Mr. Jian Min WangSecretary of the Board of Directors · born 1977
- Mr. Yi ZhangDeputy General Manager · born 1972
- Mr. Qinghai YangDeputy General Manager · born 1976
- Mr. Qixin LinDeputy General Manager · born 1979